BR112015000732A2 - - Google Patents
Info
- Publication number
- BR112015000732A2 BR112015000732A2 BR112015000732A BR112015000732A BR112015000732A2 BR 112015000732 A2 BR112015000732 A2 BR 112015000732A2 BR 112015000732 A BR112015000732 A BR 112015000732A BR 112015000732 A BR112015000732 A BR 112015000732A BR 112015000732 A2 BR112015000732 A2 BR 112015000732A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176980.6 | 2012-07-18 | ||
| EP12176978.0 | 2012-07-18 | ||
| EP12176980 | 2012-07-18 | ||
| EP12176978 | 2012-07-18 | ||
| PCT/EP2013/065250 WO2014013039A1 (en) | 2012-07-18 | 2013-07-18 | Composition comprising a mixture of cd95-fc isoforms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015000732A2 true BR112015000732A2 (pt) | 2017-08-15 |
| BR112015000732B1 BR112015000732B1 (pt) | 2023-01-10 |
Family
ID=48794121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000732-5A BR112015000732B1 (pt) | 2012-07-18 | 2013-07-18 | Composição farmacêutica compreendendo uma mistura de isoformas de cd95-fc, método para a produção da mesma e formulação |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9434783B2 (pt) |
| EP (4) | EP2875045B1 (pt) |
| JP (2) | JP6317739B2 (pt) |
| KR (1) | KR102201694B1 (pt) |
| CN (3) | CN109897115A (pt) |
| AU (2) | AU2013291984B2 (pt) |
| BR (1) | BR112015000732B1 (pt) |
| CA (2) | CA2877989C (pt) |
| DK (2) | DK2875045T3 (pt) |
| ES (2) | ES2924109T3 (pt) |
| HK (2) | HK1207096A1 (pt) |
| IL (1) | IL236659A (pt) |
| MX (1) | MX371430B (pt) |
| NZ (1) | NZ703546A (pt) |
| RU (2) | RU2648157C2 (pt) |
| SG (1) | SG11201500134QA (pt) |
| UA (1) | UA116889C2 (pt) |
| WO (2) | WO2014013037A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2875045T3 (en) * | 2012-07-18 | 2018-07-02 | Apogenix Ag | COMPOSITION comprising a mixture of CD95-FC ISOFORMs |
| JP6556121B2 (ja) * | 2013-04-29 | 2019-08-07 | アポジェニックス アーゲー | 癌を診断する方法 |
| NO2776305T3 (pt) | 2014-04-23 | 2018-01-27 | ||
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| US9587215B2 (en) | 2014-08-07 | 2017-03-07 | General Electric Company | Devices, systems and methods for automated transfer of a sample |
| WO2016106291A1 (en) * | 2014-12-22 | 2016-06-30 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| KR20220002336A (ko) | 2019-03-29 | 2022-01-06 | 미스트 쎄라퓨틱스, 엘엘씨 | T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법 |
| IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | A method for producing tumor-reactive t cells using modulatory substances |
| JP2023516636A (ja) | 2020-02-27 | 2023-04-20 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | 腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0965637B1 (en) * | 1996-05-02 | 2005-07-20 | Mochida Pharmaceutical Co., Ltd. | Fas ANTIGEN DERIVATIVES |
| ATE273713T1 (de) * | 1996-10-31 | 2004-09-15 | Mochida Pharm Co Ltd | Fas-antagonist für die prophylaxe oder therapie von gvhd |
| ES2307313T3 (es) * | 1997-02-27 | 2008-11-16 | Ono Pharmaceutical Co., Ltd. | Nuevos polipeptidos, adn que codifican y utilizan estos polpeptidos. |
| CA2309598A1 (en) * | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
| CN101684158A (zh) * | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| EP1273297A1 (en) * | 2001-07-06 | 2003-01-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| WO2004085479A2 (en) * | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
| JP2009536611A (ja) * | 2006-03-28 | 2009-10-15 | バイオファルミカ リミテッド | ホルモン依存性障害の処置のための作用物質及びその使用 |
| RU2009101783A (ru) * | 2006-06-21 | 2010-07-27 | Апогеникс Гмбх (De) | Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека |
| PL2101877T3 (pl) * | 2006-12-28 | 2013-11-29 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo |
| WO2008101671A2 (en) * | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| EP2310409A2 (en) | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
| ES2593049T3 (es) * | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
| JP5754740B2 (ja) * | 2009-07-21 | 2015-07-29 | クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ | 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム |
| US8722615B2 (en) * | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| DK2875045T3 (en) * | 2012-07-18 | 2018-07-02 | Apogenix Ag | COMPOSITION comprising a mixture of CD95-FC ISOFORMs |
| JP6556121B2 (ja) | 2013-04-29 | 2019-08-07 | アポジェニックス アーゲー | 癌を診断する方法 |
-
2013
- 2013-07-18 DK DK13742412.3T patent/DK2875045T3/en active
- 2013-07-18 AU AU2013291984A patent/AU2013291984B2/en active Active
- 2013-07-18 JP JP2015522106A patent/JP6317739B2/ja not_active Expired - Fee Related
- 2013-07-18 UA UAA201500254A patent/UA116889C2/uk unknown
- 2013-07-18 US US14/415,871 patent/US9434783B2/en active Active
- 2013-07-18 EP EP13742412.3A patent/EP2875045B1/en active Active
- 2013-07-18 EP EP18164139.0A patent/EP3409686B1/en active Active
- 2013-07-18 RU RU2015105328A patent/RU2648157C2/ru active
- 2013-07-18 EP EP18166228.9A patent/EP3406630B1/en active Active
- 2013-07-18 WO PCT/EP2013/065248 patent/WO2014013037A1/en active Application Filing
- 2013-07-18 EP EP13737631.5A patent/EP2875044B1/en not_active Not-in-force
- 2013-07-18 BR BR112015000732-5A patent/BR112015000732B1/pt active IP Right Grant
- 2013-07-18 CN CN201910254827.8A patent/CN109897115A/zh active Pending
- 2013-07-18 CN CN201380043661.6A patent/CN104640876A/zh active Pending
- 2013-07-18 SG SG11201500134QA patent/SG11201500134QA/en unknown
- 2013-07-18 MX MX2015000731A patent/MX371430B/es active IP Right Grant
- 2013-07-18 RU RU2015105330A patent/RU2648146C2/ru active
- 2013-07-18 ES ES18164139T patent/ES2924109T3/es active Active
- 2013-07-18 WO PCT/EP2013/065250 patent/WO2014013039A1/en active Application Filing
- 2013-07-18 CA CA2877989A patent/CA2877989C/en not_active Expired - Fee Related
- 2013-07-18 CA CA2878992A patent/CA2878992C/en active Active
- 2013-07-18 JP JP2015522107A patent/JP6231562B2/ja active Active
- 2013-07-18 US US14/415,866 patent/US9315570B2/en active Active
- 2013-07-18 NZ NZ703546A patent/NZ703546A/en unknown
- 2013-07-18 AU AU2013291982A patent/AU2013291982B2/en not_active Ceased
- 2013-07-18 DK DK18164139.0T patent/DK3409686T3/da active
- 2013-07-18 ES ES13742412.3T patent/ES2674662T3/es active Active
- 2013-07-18 KR KR1020157004183A patent/KR102201694B1/ko active IP Right Grant
- 2013-07-18 CN CN201380038208.6A patent/CN104662039B/zh not_active Expired - Fee Related
-
2015
- 2015-01-11 IL IL236659A patent/IL236659A/en active IP Right Grant
- 2015-08-11 HK HK15107780.2A patent/HK1207096A1/xx not_active IP Right Cessation
- 2015-08-11 HK HK15107778.6A patent/HK1207095A1/xx unknown
-
2016
- 2016-04-18 US US15/131,219 patent/US9657083B2/en active Active
- 2016-08-17 US US15/239,127 patent/US9908928B2/en active Active
-
2018
- 2018-02-22 US US15/902,175 patent/US10370441B2/en active Active
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: APOGENIX AG (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2013, OBSERVADAS AS CONDICOES LEGAIS |